新阿姆斯特丹制药

最新新闻

• 评级变动
  RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Raises Target Price to $51
  \u5e02\u573a\u8d44\u8baf · 2026/6/30
• 评级变动
  A Quick Look at Today's Ratings for NewAmsterdam Pharma(NAMS.US), With a Forecast Between $50 to $58
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  Truist Financial Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $57
  \u5e02\u573a\u8d44\u8baf · 2026/3/19
• 评级变动
  Guggenheim Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $45
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• 评级变动
  A Quick Look at Today's Ratings for NewAmsterdam Pharma(NAMS.US), With a Forecast Between $45 to $48
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• 评级变动
  H.C. Wainwright Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)
  TipRanks · 2026/5/8
• 评级变动
  Truist Financial Initiates NewAmsterdam Pharma(NAMS.US) With Buy Rating, Announces Target Price $57
  \u5e02\u573a\u8d44\u8baf · 2026/3/19
• 评级变动
  RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $47
  \u5e02\u573a\u8d44\u8baf · 2026/5/6
• 评级变动
  TD Cowen Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/2/21
• BMO Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $58
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• 评级变动
  William Blair Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/18
• 评级变动
  Piper Sandler Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $60
  \u5e02\u573a\u8d44\u8baf · 2026/8/4
• 评级变动
  Stifel Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $50
  \u5e02\u573a\u8d44\u8baf · 2026/9/8
• 评级变动
  Needham Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $48
  \u5e02\u573a\u8d44\u8baf · 2026/8/8
• H.C. Wainwright Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $52
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Cuts Target Price to $42
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• Truist Financial Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Announces Target Price $57
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• Truist Financial Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/8
• 评级变动
  A Quick Look at Today's Ratings for NewAmsterdam Pharma(NAMS.US), With a Forecast Between $50 to $52
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  BMO Capital Initiates NewAmsterdam Pharma(NAMS.US) With Buy Rating, Announces Target Price $58
  \u5e02\u573a\u8d44\u8baf · 2026/7/21

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。